Citadel Advisors’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $30.3M | Buy |
164,500
+8,200
| +5% | +$1.78M | ﹤0.01% | 2097 |
|
|
2026
Q2 | $38.3M | Buy |
156,300
+121,300
| +347% | +$26.3M | ﹤0.01% | 1836 |
|
|
2026
Q1 | $5.92M | Sell |
35,000
-44,800
| -56% | -$7.74M | ﹤0.01% | 4064 |
|
|
2025
Q4 | $14.6M | Sell |
79,800
-26,100
| -25% | -$3.64M | ﹤0.01% | 2737 |
|
|
2025
Q3 | $12.9M | Buy |
105,900
+3,400
| +3% | +$383K | ﹤0.01% | 2897 |
|
|
2025
Q2 | $10.7M | Buy |
102,500
+9,600
| +10% | +$1.02M | ﹤0.01% | 2934 |
|
|
2025
Q1 | $10.8M | Sell |
92,900
-30,600
| -25% | -$3.49M | ﹤0.01% | 2746 |
|
|
2024
Q4 | $10.4M | Buy |
123,500
+42,700
| +53% | +$3.93M | ﹤0.01% | 2931 |
|
|
2024
Q3 | $7.26M | Buy |
80,800
+6,200
| +8% | +$541K | ﹤0.01% | 3373 |
|
|
2024
Q2 | $6.01M | Sell |
74,600
-8,100
| -10% | -$600K | ﹤0.01% | 3466 |
|
|
2024
Q1 | $6.6M | Sell |
82,700
-8,000
| -9% | -$671K | ﹤0.01% | 3536 |
|
|
2023
Q4 | $7.22M | Sell |
90,700
-3,200
| -3% | -$214K | ﹤0.01% | 3277 |
|
|
2023
Q3 | $6.56M | Sell |
93,900
-49,700
| -35% | -$3.72M | ﹤0.01% | 3256 |
|
|
2023
Q2 | $10.3M | Sell |
143,600
-68,100
| -32% | -$5.02M | ﹤0.01% | 2636 |
|
|
2023
Q1 | $13.1M | Sell |
211,700
-477,900
| -69% | -$31.4M | ﹤0.01% | 2455 |
|
|
2022
Q4 | $53.2M | Sell |
689,600
-144,200
| -17% | -$8.62M | 0.01% | 1078 |
|
|
2022
Q3 | $37.2M | Buy |
833,800
+407,500
| +96% | +$20.4M | 0.01% | 1294 |
|
|
2022
Q2 | $16.3M | Buy |
426,300
+277,100
| +186% | +$8.76M | ﹤0.01% | 2068 |
|
|
2022
Q1 | $6.18M | Sell |
149,200
-130,700
| -47% | -$4.05M | ﹤0.01% | 3768 |
|
|
2021
Q4 | $10.6M | Sell |
279,900
-173,300
| -38% | -$6.38M | ﹤0.01% | 2987 |
|
|
2021
Q3 | $14.9M | Buy |
453,200
+255,200
| +129% | +$9.9M | ﹤0.01% | 2430 |
|
|
2021
Q2 | $13.4M | Sell |
198,000
-9,000
| -4% | -$540K | ﹤0.01% | 2636 |
|
|
2021
Q1 | $11.7M | Buy |
207,000
+44,000
| +27% | +$3.1M | ﹤0.01% | 2745 |
|
|
2020
Q4 | $13.3M | Buy |
163,000
+800
| +0.5% | +$59.8K | ﹤0.01% | 2272 |
|
|
2020
Q3 | $11.6M | Buy |
162,200
+36,100
| +29% | +$2.81M | ﹤0.01% | 2122 |
|
|
2020
Q2 | $10.4M | Sell |
126,100
-27,500
| -18% | -$2.12M | ﹤0.01% | 2168 |
|
|
2020
Q1 | $9.04M | Sell |
153,600
-15,400
| -9% | -$1.25M | ﹤0.01% | 1970 |
|
|
2019
Q4 | $17.5M | Buy |
169,000
+91,000
| +117% | +$3.68M | 0.01% | 1610 |
|
|
2019
Q3 | $1.58M | Buy |
78,000
+48,800
| +167% | +$1.25M | ﹤0.01% | 4849 |
|
|
2019
Q2 | $752K | Sell |
29,200
-27,800
| -49% | -$557K | ﹤0.01% | 6169 |
|
|
2019
Q1 | $811K | Buy |
+57,000
| New | +$529K | ﹤0.01% | 5970 |
|
Other funds holding AXSM
Citadel Advisors's AXSM Position: Q3 2026 in Review
Citadel Advisors reduced its Axsome Therapeutics (AXSM) stake by 92% in Q3 2026, selling an estimated $51.3M and leaving 19,864 shares worth $3.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5462.
Citadel Advisors first reported a position in AXSM in Q3 2016 and has held it in 33 quarters since. The position peaked at $91.3M in Q1 2024. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Citadel Advisors held 19,864 shares of Axsome Therapeutics worth $3.66M as of Q3 2026.
- Citadel Advisors sold 236,014 Axsome Therapeutics shares in Q3 2026, an estimated $51.3M.
- Axsome Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #5462 holding.
- Citadel Advisors first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 33 quarters since.
- Citadel Advisors's Axsome Therapeutics position peaked at $91.3M in Q1 2024.
- 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.